Liberty Defense Secures Contract with Acclaimed Infectious Disease Laboratory for HEXWAVE(TM) Walkthrough Screening System

Executive Summary

• Liberty Defense announced a signed sale to a prominent Infectious Disease Laboratory for deployment of its HEXWAVE™ walkthrough screening system.
• The contract expands Liberty’s custom clientele into high‑security research facilities, highlighting the versatility and market demand for its AI‑based detection technology.
• The company also disclosed shareholder approval of its 2025 Omnibus Incentive Plan, authorizing new equity‑based compensation up to 10% of outstanding shares.

Key Details

• Contract Win: Sale of HEXWAVE™ system to a world‑class infectious disease research facility for screening employees and visitors.
• System Capabilities: Active millimeter‑wave imaging combined with AI; detects metallic and non‑metallic threats, liquids, gels, powders, ceramics, etc.; contactless, high‑volume throughput; integrates with existing security, video, and access‑control systems.
• Customer Profile: Leading infectious disease laboratory focused on pathogen research, diagnostics, vaccines, and treatments—highly regulated environment requiring stringent security.
• CEO Quote: “We continue to diversify our custom clientele with HEXWAVE… The award came after a successful on‑site trial, and our continued collaboration … delivers the advanced detection performance they require.” – Bill Frain, CEO.
• Incentive Plan Update: 2025 Omnibus Incentive Plan approved at AGM (Dec 12 2025) and cleared by TSX Venture Exchange; authorizes stock options, restricted share units, deferred share units; caps issuable shares at ≤10% of outstanding common shares; replaces prior plan.
• Regulatory Filings: Plan documents available on SEDAR+.

Notable Quotes

“We continue to diversify our custom clientele with HEXWAVE, especially with organizations where safety and security are paramount,” – Bill Frain, CEO, Liberty Defense.